The debate continues about whether the patents on Covid-19 vaccines should be waived to allow low-income countries to produce doses for themselves. In current circumstances, such a course of action is likely to have little effect for good or ill, argue Michele Boldrin, David Levine, and Flavio Toxvaerd.
Researchers collaborating for the endgame of the pandemic.